ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Nephros Inc

Nephros Inc (NEPH)

2.19
-0.08
(-3.52%)
Closed March 29 04:00PM
2.23
0.04
(1.83%)
After Hours: 07:59PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
2.19
Bid
2.17
Ask
2.36
Volume
3,277
2.23 Day's Range 2.3499
1.02 52 Week Range 4.0434
Market Cap
Previous Close
2.27
Open
2.29
Last Trade
2
@
2.19
Last Trade Time
Financial Volume
$ 7,516
VWAP
2.2936
Average Volume (3m)
20,159
Shares Outstanding
10,484,932
Dividend Yield
-
PE Ratio
-3.17
Earnings Per Share (EPS)
-0.7
Revenue
9.98M
Net Profit
-7.38M

About Nephros Inc

Nephros Inc is a commercial stage company that develops and sells high performance liquid purification filters for both medical device and commercial markets. Nephros Inc is a commercial stage company that develops and sells high performance liquid purification filters for both medical device and commercial markets.

Sector
Surgical,med Instr,apparatus
Industry
Surgical,med Instr,apparatus
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Nephros Inc is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker NEPH. The last closing price for Nephros was $2.27. Over the last year, Nephros shares have traded in a share price range of $ 1.02 to $ 4.0434.

Nephros currently has 10,484,932 shares outstanding. The market capitalization of Nephros is $23.38 million. Nephros has a price to earnings ratio (PE ratio) of -3.17.

NEPH Latest News

Nephros Announces Fourth Quarter and Fiscal Year 2023 Financial Results

Full-Year Net Revenue of $14.2 Million and Fourth-Quarter Net Revenue of $3.3 Million SOUTH ORANGE, NJ, March 07, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (Nasdaq: NEPH), a...

Nephros Schedules Conference Call for Fourth Quarter and Fiscal Year 2023 Financial Results

SOUTH ORANGE, NJ, Feb. 29, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Nephros Announces Results for Quarter Ended September 30, 2023

Third-Quarter Net Revenue of $3.7 Million, a 55% Increase Over 2022; Net Loss from Continuing Operations Narrows 85% to $0.2 Million; $1.1 Million in Positive Year-to-Date Net Cash Flows from...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

false Q3 --12-31 0001196298 Yes Yes...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.06-2.666666666672.252.49432.1684122.29602939CS
4-0.88-28.6644951143.073.26322.02200932.63439678CS
12-1.61-42.36842105263.83.92.02201593.22288488CS
260.746.97986577181.494.04341.43225852.95462956CS
521.17114.7058823531.024.04341.02333302.07897309CS
156-5.42-71.22207621557.6111.66590.9051292982.63697725CS
260-4.56-67.55555555566.7511.66590.9051241643.77114255CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 22.08
(364.84%)
31.9M
NXLNexalin Technologies Inc
$ 1.50
(92.31%)
11.67M
CEROCERo Therapeutics Holdings Inc
$ 3.112
(90.92%)
24.08M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
KYCHKeyarch Acquisition Corporation
$ 12.30
(75.58%)
196.62k
BOLDBoundless Bio Inc
 14.25
(-76.24%)
767.63k
PMECPrimech Holdings Ltd
$ 1.2999
(-66.50%)
8.28M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.1816
(-44.45%)
21.92M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
NBSTWNewbury Street Acquisition Corporation
$ 0.042279
(-38.28%)
1.75k
NKLANikola Corporation
$ 1.035
(13.85%)
163.84M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
MARAMarathon Digital Holdings Inc
$ 22.56
(2.22%)
86.14M
AKANAkanda Corporation
$ 0.1166
(-29.29%)
80.34M

NEPH Discussion

View Posts
Simonzx2 Simonzx2 6 months ago
new CEO has a lot of relevant experience... stock free cash flow positive for the first time since 2019,barely
👍️0
Banjo50 Banjo50 10 months ago
IS THIS STOCK A SCAM OR WHAT??? I WANT THE TRUTH!!!
👍️0
whymea whymea 4 years ago
Tony Robinson appointed VP of Operations

Did anyone conduct an interview???

Former COO of CVR Medical Corp.

CVR is embroiled in a complete melt down including Months Long Trading Halt, Regulator Complaints, Officer and Board Resignations, etc. etc...

Check it out yourselves.
https://investorshub.advfn.com/CVR-Medical-CRRVF-31902/

Will it be same path for Nephros??

Good luck too all... But you know there is no such thing as luck. Do you???


https://www.google.com/url?rct=j&sa=t&url=https://finance.yahoo.com/news/specialty-renal-products-announces-appointment-113010721.html&ct=ga&cd=CAEYACoTNjQ4NzgzMTcxODY0ODE3NTM5OTIaZmMwMWYzNzEzMDg5NzBkZTpjb206ZW46VVM&usg=AFQjCNFLK2fj0BSn9_cTYMzGog-9d3292Q
👍️0
236T568 236T568 4 years ago
TIMBER! 493,827 Shares of NEPH Common Stock declared effective by the SEC and are now freely trading after the 6 month lock-up agreement ends November 15, 2019


https://www.otcmarkets.com/filing/html?id=13688528&guid=2q-SUaH2vzeKx3h#FORM424B3_HTM_A_006
👍️0
whytestocks whytestocks 4 years ago
News: $NEPH Nephros Announces Preliminary Financial Results for Third Quarter 2019

Anticipates $3.1 Million Product Revenue, 85% Growth Over 2018 Increases Full-Year Revenue Guidance to $9.5-10 Million SOUTH ORANGE, NJ, Oct. 07, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nephros, Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells hi...

Find out more NEPH - Nephros Announces Preliminary Financial Results for Third Quarter 2019
👍️0
Banjo50 Banjo50 5 years ago
I think it should be five cents. I will buy several hundred shares at five cents per share.
👍️0
jvg25 jvg25 5 years ago
i think they call that putting lipstick on a pig.
👍️0
Renee Renee 5 years ago
NEPH moved to the Nasdaq from the OTC:

https://otce.finra.org/otce/dailyList?viewType=Deletions
👍️0
rs99 rs99 5 years ago
08/14/2019 01:46:03 Market Center Change Listed on NASDAQ
08/14/2019 01:46:03
NEPH
Nephros, Inc. Common Stock
👍️0
Renee Renee 5 years ago
NEPH one for 9 reverse split. PPS closed at .62.

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
👍️0
Banjo50 Banjo50 5 years ago
It should be five cents. Once it gets to five cents I will buy up to 792 shares, but not before it gets to five cents.
👍️0
Banjo50 Banjo50 5 years ago
I think it should be five cents. I bid five cents per share for a full 150 shares.
👍️0
whytestocks whytestocks 5 years ago
News: $NEPH Nephros Announces Preliminary Financial Results for First Quarter 2019

Anticipates $1.7 Million Revenue; Year-over-Year Growth Exceeds 75% SOUTH ORANGE, NJ, April 08, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device and commercial products company that develops and sells high performance wa...

Read the whole news https://marketwirenews.com/news-releases/nephros-announces-preliminary-financial-results-for-first-quarter-2019-7962048.html
👍️0
willlbone willlbone 6 years ago
Dilution. Retest the lows.
👍️0
riskon riskon 6 years ago
NEPH Chart Looking Nice
👍️0
morasco68 morasco68 6 years ago
Nephros Inc. to present at The Microcap Conference.
👍️0
bgseth bgseth 6 years ago
SeeThruEquity Issues Update on Nephros (NEPH) with Target Price of $1.80

https://finance.yahoo.com/news/seethruequity-issues-nephros-neph-target-140000345.html;_ylc=X1MDMTE5Nzc4NDE4NQRfZXgDMQRfeXJpZANmMzVsMGp0ZGE1djg5BGcDZFhWcFpEeHVjejR5TldJeVpURm1NQzB5T0RnMUxUTmhZVEF0T0dZMVpTMWhPV0kzWlRZNU56WTBZelYxZFdsa1BHNXpQazVGVUVnPQ0KBGxhbmcDZW4tVVMEb3JpZ19sYW5nA2VuBG9yaWdfcmVnaW9uA1VTBHBvcwMwBHJlZ2lvbgNVUwRzeW1ib2wDTkVQSA--?.tsrc=applewf
👍️0
Nistel Nistel 6 years ago
Some action here today. Nice move up on decent volume.
👍️0
hawk37 hawk37 6 years ago
Still buying this
👍️0
carbonfiltered carbonfiltered 6 years ago
Surprised it hasn’t moved..... this could be a sleeper
👍️0
Nistel Nistel 6 years ago
Nephros Announces Preliminary Financial Results for Fourth Quarter 2017
Jan 04, 2018
OTC Disclosure & News Service

-

Anticipates Over 80% Year-over-Year Product Revenue Growth for the Quarter

SOUTH ORANGE, NJ, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration (HDF) system for use with a hemodialysis (HD) machine for the treatment of patients with End Stage Renal Disease (ESRD), today announced preliminary financial results for the fourth quarter of 2017.

Nephros expects product revenue for the fourth quarter ended December 31, 2017, to be approximately $1,258,000, an increase of approximately 83% over the same period in 2016. Total revenue for the quarter ended December 31, 2017 is projected to exceed $1,300,000, an increase of more than 75% over the same period in 2016.

Net cash used in operating activities for the fourth quarter 2017 is expected to be approximately $38,000 including approximately $65,000 of cash paid for interest on outstanding notes. Nephros ended the quarter with approximately $2.2 million in cash.

“While we have a long way to go to reach our full potential, we continue to gain traction in the market with our product offerings and to successfully compete for large, multi-year filtration contracts,” said Daron Evans, CEO of Nephros. “In addition to solid quarterly revenue growth and a strong year-end cash balance, we were essentially cash flow neutral from an operational basis this quarter. For 2018, we foresee a continuation of our growth in medical filter sales, an expansion of our commercial and industrial filter sales, and the ability to invest proceeds into our second generation HDF system.”
👍️0
D_rwc D_rwc 6 years ago
Holding the line....

So far it looks like sellers are not giving in. That's a good sign. Hang in there guys
👍️0
barelyalive69 barelyalive69 6 years ago
Definitely looks like they are heading into a rapid growth stage. Could certainly end up being a short term 4-bagger for those buying now.
👍️0
shotcallers shotcallers 6 years ago
Seems like they are over a huge hurdle.
👍️0
D_rwc D_rwc 6 years ago
Revenue of $915,000?

Now this is based on sales and has nothing to do with the tax credits or selling their operating loses correct?

>>>
The Company expects total revenue for the third quarter ending September 30, 2017 of approximately $915,000, an increase of approximately 95% over the same period in 2016. Based upon the anticipated sales trajectory, the Company believes that it can be sustainably cash flow positive around the end of 2017.
👍️0
shotcallers shotcallers 6 years ago
Still here for a very long time
👍️0
D_rwc D_rwc 6 years ago
I'm surprised no one is talking about NEPH. They claim to be cash flow positive in the next few months and short interest has declined slightly.
👍️0
hawk37 hawk37 7 years ago
Anyone here?
👍️0
silversmith silversmith 7 years ago
👍️0
silversmith silversmith 7 years ago
👍️0
silversmith silversmith 7 years ago
👍️0
silversmith silversmith 7 years ago
👍️0
Cruzer98 Cruzer98 8 years ago
Conf coming up

http://finance.yahoo.com/news/nephros-announces-participation-18th-annual-113000293.html
👍️0
©PROPHETABLE ©PROPHETABLE 8 years ago
She's tryin
👍️0
blindjohn blindjohn 8 years ago
LezzzzGo
👍️0
blindjohn blindjohn 8 years ago
Ughh
👍️0
stocktrademan stocktrademan 8 years ago
NEPH bullish 0.38




👍️0
Cruzer98 Cruzer98 8 years ago
So are the filters selling?
👍️0
dranesthesia1 dranesthesia1 8 years ago
What were you short? Lol
👍️0
©PROPHETABLE ©PROPHETABLE 8 years ago
Ugh...
👍️0
seven-up seven-up 8 years ago
Roll on NEPH
👍️0
Nistel Nistel 8 years ago
Finally someone noticed. Good price action today, with some volume. Stock is too much under the radar.
👍️0
seven-up seven-up 8 years ago
NEPHROS RECEIVES FDA 510(K) CLEARANCE OF S100 POINT OF USE FILTER
RIVER EDGE, NJ, April 14, 2016– Nephros, Inc. (OTCQB:NEPH), (the “Company”) a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration (“HDF”) system for use with a hemodialysis machine for the treatment of patients with end stage renal disease, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) to market its S100 Point of Use filter designed to filter Environmental Protection Agency (“EPA”) quality drinking water to retain waterborne bacteria to assist in infection control.
The S100 ultrafilter is designed to assist hospitals and medical facilities with their efforts to protect patients from water-borne bacteria. Legionella and Pseudomonas are common bacteria that can have a devastating impact on infected patients, particularly those whose immune system is compromised. The S100 Point of Use filter attaches to the end of a sink faucet and is designed to provide up to 3 months of protection.
“In response to customer feedback, the S100 adds an end of faucet product to our infection control portfolio to support hospitals in their efforts to protect patients from water-borne pathogens,” said Daron Evans, President and CEO of Nephros. “With the 510(k) process completed, we intend to fill initial orders for S100 filters this quarter.”
About Nephros, Inc.
Nephros is a commercial stage medical device company that develops and sells high performance liquid purification filters, as well as a hemodiafiltration system for the treatment of patients with End Stage Renal Disease. Its filters, which it calls ultrafilters, are used primarily in medical applications. Nephros ultrafilters are used by dialysis centers for the removal of biological contaminants from the water and bicarbonate concentrate feeding hemodialysis devices. Additionally, Nephros ultrafilters are used in hospitals and medical clinics as an aid in infection control by retaining bacteria (i.e. Legionella, Pseudomonas), virus and endotoxin from water used by patients.
For more information about Nephros, please visit the company’s website at www.nephros.com.
Forward-Looking Statements
This release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the S100, including the timing of filling initial orders for such product, and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, the availability of capital when needed, our dependence on third party manufacturers, regulatory reforms, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Nephros Inc.’s reports filed with the U.S. Securities and Exchange Commission, including with respect to Nephros, its Annual Report on Form 10-K for the year ended December 31, 2015. Nephros, Inc. does not undertake any responsibility to update the forward-looking statements in this release.

Contact:

Investor:
PCG Advisory Group
Kirin M. Smith, Chief Operating Officer
Direct: 646-863-6519
www.pcgadvisory.com
POST NAVIGATION
? Nephros Reports 2015 Fourth Quarter and Full Year Financial Results; Provides 2016 Guidance and Potential Upcoming Milestones
×
Close
HOME
DIALYSIS
INFECTION CONTROL
HDF
PRODUCT RESOURCES
PRESS
TEAM
CORPORATE GOVERNANCE
INVESTOR RELATIONS
CONTACT



HEMODIAFILTRATION SYSTEMS
ADD THE POWER OF CONVECTION TO YOUR DIALYSIS
LEARN MORE›

INFECTION CONTROL FILTERS
THE SOLUTION FOR ULTIMATE PROTECTION
LEARN MORE›

HEMODIAFILTRATION SYSTEMS
ADD THE POWER OF CONVECTION TO YOUR DIALYSIS
LEARN MORE›

INFECTION CONTROL FILTERS
THE SOLUTION FOR ULTIMATE PROTECTION
LEARN MORE›

HEMODIAFILTRATION SYSTEMS
ADD THE POWER OF CONVECTION TO YOUR DIALYSIS
LEARN MORE›

INFECTION CONTROL FILTERS
THE SOLUTION FOR ULTIMATE PROTECTION
LEARN MORE›

DIALYSIS FILTERS
BETTER WATER = IMPROVED PATIENT WELLBEING
LEARN MORE›

HEMODIAFILTRATION SYSTEMS
ADD THE POWER OF CONVECTION TO YOUR DIALYSIS
LEARN MORE›

INFECTION CONTROL FILTERS
THE SOLUTION FOR ULTIMATE PROTECTION
LEARN MORE›

HEMODIAFILTRATION SYSTEMS
ADD THE POWER OF CONVECTION TO YOUR DIALYSIS
LEARN MORE›

INFECTION CONTROL FILTERS
THE SOLUTION FOR ULTIMATE PROTECTION
LEARN MORE›

HEMODIAFILTRATION SYSTEMS
ADD THE POWER OF CONVECTION TO YOUR DIALYSIS
LEARN MORE›

INFECTION CONTROL FILTERS
THE SOLUTION FOR ULTIMATE PROTECTION
LEARN MORE›
1
2
3
4
5
6
7
8
9
10
11
PrevNext
1
2
3
4
5
6
7
8
9
PrevNext
1
2
3
4
5
6
7
PrevNext
1
2
3
4
5
PrevNext
1
2
3
PrevNext

DIALYSIS CLINICS

DIALYSIS ULTRAFILTERS

HEMODIAFILTRATION SYSTEMS
HOSPITAL

INFECTION CONTROL ULTRAFILTERS
INDUSTRIAL

COMMERCIAL ULTRAFILTERS

LATEST NEWS

04/14/2016
Nephros Receives FDA 510(k) Clearance of S100 Point of Use Filter
03/30/2016
Nephros Reports 2015 Fourth Quarter and Full Year Financial Results; Provides 2016 Guidance and Potential Upcoming Milestones
03/16/2016
Nephros Launches SSUmini and Provides S100 Update
VIEW PRESS RELEASE ARCHIVES>
UPCOMING EVENTS

QUICK LINKS

Partner Links
Commercial Product Downloads
FDA-cleared Product Downloads
VIEW ALL RESOURCES >

For Customer Service and Product Information
Email: filters@nephros.com
Call: (201) 343-5202
DIALYSIS ULTRAFILTERS
DSU-D
SSU-D
HEMODIAFILTRATION
OLpur® H2H Hemodiafiltration Module
OLpur® MD220 Hemodiafilter
INFECTION CONTROL
Ice Machines
Showers
Sinks
INDUSTRIAL
Coming Soon
COMPANY
Home
Upcoming Events
Press Releases
Contact Us
Investor Relations

© Copyright 2016 Nephros, Inc. | All Rights Reserved
41 Grand Ave. River Edge, NJ 07661 Tel: 201.343.5202 Fax: 201.343.5207 info@nephros.com
👍️0
seven-up seven-up 8 years ago
Nephros Launches SSUmini and Provides S100 Update

Mar 16, 2016 07:30:00 (ET)

RIVER EDGE, N.J.--(BUSINESS WIRE)--March 16, 2016--
Nephros, Inc. (OTCQB:NEPH) (the "Company"), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration ("HDF") system for use with a hemodialysis machine for the treatment of patients with end stage renal disease, announces the release of the SSUmini, a smaller version of its SSU-D medical device.

SSUmini Launch

The SSUmini was developed as a compact, economical solution to provide hemodialysis quality water as a polish filter for smaller, portable reverse osmosis ("RO") systems and to provide hemodialysis quality bicarbonate concentrate for dialysis clinics with centralized bicarbonate systems. For low-flow rate situations, the SSUmini can provide protection from bacteria, viruses and endotoxins for up to 12 months. The SSUmini is a medical device with U.S. Food and Drug Administration ("FDA") 510(k) clearance. Details on the SSUmini can be found at www.nephros.com/dialysis.

"We have been working with multiple dialysis water system suppliers and have identified an area where we believe our filter technology could add additional value," said Monet Carnahan, Director of Dialysis Products at Nephros. "The SSUmini is small enough to fit inside most portable RO systems, enabling our partners to supply the product as an OEM part. It also provides a low-cost, long-life polish filter for those dialysis clinics that centrally mix their bicarbonate concentrate."

The SSU-10 is also now available. The SSU-10 is ideal as a polish filter for smaller RO systems, either on the laboratory benchtop or in the home setting under the sink. The SSU-10 is not a medical device.

S100 510(k) Update

The Company filed for 510(k) clearance for its S100 Point of Use microfilter with the FDA in late October 2015. In late December 2015, the FDA requested additional information. On March 8, 2016, the Company submitted a package to the FDA with supplemental information. Pending FDA clearance, the Company aims to launch the S100 in the second quarter of 2016.

About Nephros, Inc.

Nephros is a commercial stage medical device company that develops and sells high performance liquid purification filters, as well as a hemodiafiltration system for the treatment of patients with End Stage Renal Disease. Its filters, which it calls ultrafilters, are used primarily in medical applications. Nephros ultrafilters are used by dialysis centers for the removal of biological contaminants from the water and bicarbonate concentrate feeding hemodialysis devices. Additionally, Nephros ultrafilters are used in hospitals and medical clinics as an aid in infection control by retaining bacteria (i.e. Legionella, Pseudomonas), virus and endotoxin from water used by patients.

For more information about Nephros, please visit the company's website at www.nephros.com.

Forward-Looking Statements

This release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the timing of the Company's responses to the FDA relating to its 510(k) submission for its S100 product; feedback from customers regarding our new products; the timing of planned deliveries of products to the Company's distributors and partners; our plans to expand our product line, our expectations related to the receipt of FDA clearance on new products; our plan to expand into additional market segments; our plan to grow revenues sufficient to generate positive cash flow, and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, uncertainties in the FDA clearance process, the acceptance of our product offerings by customers and end users, and the availability of sufficient capital to fund our operating activities. These and other risks and uncertainties are detailed in Nephros Inc.'s reports filed with the U.S. Securities and Exchange Commission, including with respect to Nephros, its Annual Report on Form 10-K for the year ended December 31, 2014. Nephros, Inc. does not undertake any responsibility to update the forward-looking statements in this release.

View source version on businesswire.com: www.businesswire.com/news/home/20160316005289/en/


CONTACT: Investor:
PCG Advisory Group

Kirin M. Smith, 646-863-6519

Chief Operating Officer

www.pcgadvisory.com


SOURCE: Nephros, Inc.
Copyright Business Wire 2016

(END) Dow Jones Newswires

March 16, 2016 07:30 ET (11:30 GMT)





















































👍️0
seven-up seven-up 8 years ago
Multiple product lines based on proprietary filtration technology
- Ultrafilters for dialysis water and bicarbonate
- Ultrafilters to aid in infection control in hospitals
- Hemodiafiltration systems to provide dialysis for end stage renal patients
• Ultrafilter business unit has $100M+ revenue potential:
- Distributor-based sales model into dialysis clinics and hospitals
- ASHRAE 188-2015, a recently approved industry guideline that is
generating high-levels of focus on waterborne pathogen protection
- Multiple partnering opportunities for ultrafilters as OEM components
• Hemodiafiltration (HDF) System business unit has $100M+ revenue
potential with minimal market penetration
- 4% market share of dialysis patients = $100M in revenue from
disposables from HDF system
• Royalties and profit sharing from license to CamelBak® in Military
Recreation market
👍️0
seven-up seven-up 8 years ago
Great buy in for the this stock....
👍️0
seven-up seven-up 8 years ago
Great buy in point....
👍️0
seven-up seven-up 8 years ago
Big things in the work at NEPH
👍️0
seven-up seven-up 8 years ago
2016 going to be strong for NEPH
👍️0
seven-up seven-up 8 years ago
Get ready 510k with FDA fixing to be approved
👍️0

Your Recent History

Delayed Upgrade Clock